Salarius Pharmaceuticals, Inc.

Clinical-stage biopharma developing targeted protein therapies for cancer and viral diseases.

SLRX | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 2450 HOLCOMBE BLVD, 77021 HOUSTON
Website:: https://salariuspharma.com/
Sector:: Mining and quarrying
Industry:: Mining of non-ferrous metal ores

Description

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with cancer and other diseases with high unmet medical needs. The company's technology aims to correct the dysregulated gene expression that drives disease progression. Its pipeline is built on two primary drug classes: targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs). The lead TPI candidate, seclidemstat (SP-2577), is in Phase 1/2 clinical trials for solid and hematologic cancers like leukemias and lymphomas. The company's TPD candidate, SP-3164, is in IND-enabling studies. Following a merger with Decoy Therapeutics, Salarius is also advancing peptide therapeutics for cancer and respiratory viruses.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Salarius Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Salarius Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Salarius Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Camino Minerals Corporation Advancing high-grade copper and precious metal projects from discovery to production.	Canada	COR
Cantargia Develops antibody treatments targeting IL1RAP for cancer and autoimmune/inflammatory diseases.	Sweden	CANTA
Captor Therapeutics S.A. Developing TPD therapeutics for oncology and autoimmune diseases with its Optigrade™ platform.	Poland	CTX
Cardiff Oncology, Inc. Clinical-stage biotech developing a PLK1 inhibitor to treat resistant cancers.	United States of America	CRDF
Cardio Diagnostics Holdings, Inc. AI-powered epigenetic and genetic tests for early detection of heart disease risk.	United States of America	CDIO
Cardiol Therapeutics Inc. Develops oral cannabidiol therapies for inflammatory and fibrotic heart diseases.	United States of America	CRDL
CareDx, Inc. Precision diagnostics and surveillance solutions for the organ transplant journey.	United States of America	CDNA
CAREERLINK CO.,LTD. Offers one-stop BPO, CRM, and staffing for admin, manufacturing, and logistics.	Japan	6070
Caris Life Sciences, Inc. Pioneering precision cancer care via AI-powered molecular profiling and diagnostics.	United States of America	CAI
Carna Biosciences, Inc. Develops kinase inhibitor drugs for oncology/autoimmune diseases & offers discovery support services.	Japan	4572